PMID: 25002025
Tirzepatide (MOUNJARO) Pronounced: tir ZEP a tide / mown JAHR OH Mnemonic: Tear zeppelin (over) Mount (Kiliman)jaro Year of release: 2022 Cost: $1060 / mo FDA-approved for: Type 2 diabetes Mechanism: dual GLP-1/GIP receptor agonist Available doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg (weekly subcutaneous injection) Dynamic interactions: Glucose lowering Kinetic interactions: Delayed gastric emptying, otherwise none significant in a bubble Tirzepatide (Mounjaro) is the first twincretin for type 2 diabetes
BCBS Federal (FEP) Different Rules Than Everyone Else If you're a federal employee, your BCBS plan follows national federal rules, not your state's rules
Use of multivitamins, intake of B vitamins and risk of ovulatory infertility
Improve skin texture and tone , minimizing acne scars or other imperfections
Appetite suppressants. November 20, 2023